• 1
    Yawn BP, Yunginger JW, Wollan PC, Reed CE, Silverstein MD, Harris AG. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999;103: 5459.
  • 2
    Leynaert B, Neukirch F, Demoly P, Bousquet J. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol 2000;106(Suppl. 5):S201S205.
  • 3
    Togias A. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol 2003;111: 11711183.
  • 4
    Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. Allergy 2003;58: 691706.
  • 5
    Schmidt D, Watson N, Ruehlmann E, Magnussen H, Rabe KF. Serum immunoglobulin E levels predict human airway reactivity in vitro. Clin Exp Allergy 2000;30: 233241.
  • 6
    Schramm B, Ehlken B, Smala A, Quednau K, Berger K, Nowak D. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-yr retrospective study. Eur Respir J 2003;21: 116122.
  • 7
    Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol 2002;109: 5762.
  • 8
    Adams RJ, Fuhlbrigge AL, Finkelstein JA, Weiss ST. Intranasal steroids and the risk of emergency department visits for asthma. J Allergy Clin Immunol 2002;109: 636642.
  • 9
    Passalacqua G, Canonica GW. Treating the allergic patient: think globally, treat globally. Allergy 2002;57: 876883.
  • 10
    Bousquet J, Van Cauwenberge P, Khaltaey N. Allergic rhinitis and its impact on asthma (ARIA) Workshop Report. J Allergy Clin Immunol 2001;108(Suppl. 5):S147S334.
  • 11
    MacGlashan DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997;158: 14381445.
  • 12
    Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108: 184190.
  • 13
    Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18: 254261.
  • 14
    Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F et al. The anti-IgE antibody omalizumab improves asthma related quality of life in patients with allergic asthma. Eur Respir J 2002;20: 10881094.
  • 15
    Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 2001;17: 233240.
  • 16
    Finn A, Gross G, van Bavel J, Lee T, Windom H, Everhard F et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 2003;111: 278284.
  • 17
    Casale TB, Condemi J, LaForce C, Nayak A, Rowe M, Watrous M. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001;286: 29562967.
  • 18
    Ädelroth E, Rak S, Haahtela T, Aasand G, Rosenhall L, Zetterstrom O et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106: 253259.
  • 19
    Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A et al. Omalizumab, an anti-immunoglobulin E antibody, is effective and well tolerated in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91: 160167.
  • 20
    Bousquet J, Harnest U, Chung KF, Oshinyemi K, Blogg M. Omalizumab improves symptom control in patients with poorly controlled allergic asthma and concomitant rhinitis. J Allergy Clin Immunol 2003;111: A295.
  • 21
    Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. Am Rev Respir Dis 1993;147: 828832.
  • 22
    Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21: 7783.
  • 23
    National asthma education and prevention programme. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. National Institutes of Health 1997. Pub. no. 98–4051: Bethesda, MD.
  • 24
    National Institutes of Health. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2002. No. 02–3659. Bethesda, MD.
  • 25
    Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the asthma quality of life questionnaire. Chest 1999;115: 12651270.
  • 26
    Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47: 8187.
  • 27
    Wasserfallen JB, Gold K, Schulman KA, Baraniuk JN. Development and validation of a rhinoconjunctivitis and asthma symptom score for use as an outcome measure in clinical trials. J Allergy Clin Immunol 1997;100: 1622.
  • 28
    Maurer W, Hothorn L, Lehmacher W. Multiple comparisons in drug trials and pre-clinical assays a-priori ordered hypothesis. In: VollmarJ, editor. Biometrie in der chemisch-pharmazeutischen Industrie 6. Testing principles in clinical and preclinical trials. Stuttgart: Gustav Fischer, 1995: 315.
  • 29
    Verlato G, Corsico A, Villani S, Cerveri I, Migliore E, Accordini S et al. Is the prevalence of adult asthma and allergic rhinitis increasing? Results of an Italian study. J Allergy Clin Immunol 2003;111: 12321238.
  • 30
    Baiardini I, Pasquali M, Giardini A, Specchia C, Passalacqua G, Venturi S et al. Rhinasthma: a new specific QoL questionnaire for patients with rhinitis and asthma. Allergy 2003;58: 289294.
  • 31
    Green RH, Brightling CE, Pavord ID, Wardlaw AJ. Management of asthma in adults: current therapy and future directions. Postgrad Med J 2003;79: 259267.
  • 32
    Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91: 154159.
  • 33
    Corren J, Casale T, Deniz Y, Ashby M. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol 2003;111: 8790.
  • 34
    Juniper EF. Effect of asthma on quality of life. Can Respir J 1998;5(Suppl. A):77A84A.
  • 35
    Meltzer EO, Nathan RA, Selner JC, Storms W. Quality of life and rhinitic symptoms: Results of a nationwide survey with the SF-36 and RQLQ questionnaires. J Allergy Clin Immunol 1997;99: S815S819.
  • 36
    Leynart BJ, Neukirch F, Liard R, Bousquet J, Neukirch C. Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 2000;162: 13911396.
  • 37
    Gerth van Wijk R. Allergy: a global problem. Quality of life. Allergy 2002;57: 10971110.
  • 38
    Joyce DP, Jackevicius C, Chapman KR, McIvor RA, Kesten S. The placebo effect in asthma drug therapy trials: a meta-analysis. J Asthma 2000;37: 303318.
  • 39
    Graft D, Aaronson D, Chervinsky P, Kaiser H, Melamed J, Pedinoff A et al. A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray. J Allergy Clin Immunol 1996;98: 724731.